Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight's 'Parkinson's disease Levodopa-induced dyskinesia (PD-LID) - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of PD-LID in the United States, Japan, EU4 (Germany, Spain, Italy, France) and the UK.

The Parkinson's disease Levodopa-induced dyskinesia (PD-LID) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Parkinson's disease Levodopa-induced dyskinesia (PD-LID) market size from 2019 to 2032, segmented by the 7MM. The report also covers the current Parkinson's disease Levodopa-induced dyskinesia (PD-LID) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

• The United States
• EU4 + United Kingdom
• Japan

Study period: 2019-2032

Parkinson's disease Levodopa-induced dyskinesia (PD-LID): Disease Understanding and Treatment Algorithm

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Overview

According to the Parkinson's Foundation, Parkinson's disease (PD) is a neurodegenerative disorder that affects dopamine-producing (dopaminergic) neurons predominately in a specific area of the brain called the substantia nigra.

Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacological approaches (such as exercise, occupational, and speech therapies). Approaches such as deep brain stimulation (DBS) and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremors, worsening symptoms when the medication wears off, and dyskinesias.

Levodopa (L-DOPA) is the most effective drug for treating PD, but motor fluctuations and dyskinesia complicate its long-term use. Dyskinesia may be mild initially but may progress to a disabling symptom and interfere with the quality of life. Three types of dyskinesias are identified: off-period dystonia, peak dose dyskinesia, and diphasic dyskinesia. Off-time dyskinesia is usually encountered during the night or early morning. Thus, administering L-DOPA formulations with a longer half-life at night can effectively treat off-time dyskinesia. However, diphasic dyskinesia is treated by increasing the dose of dopaminergic drugs administered; contrarily, peak dose dyskinesia is generally performed by reducing the dose of the dopaminergic drug administered.

The treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias are the most difficult to treat, particularly in patients with young-onset PD. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require DBS to control their troublesome motor fluctuations and LIDs. Various emerging drugs currently in development promise to provide better control of LIDs and other levodopa-related complications shortly.

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Epidemiology

The Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology segmented as the number of patients developing Parkinson's disease Levodopa-induced dyskinesia (PD-LID) and type-specific cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID). The report includes the total cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID) in the 7MM covering the United States, Japan, EU4 and the United Kingdom from 2019 to 2032.

Country-wise Parkinson's disease levodopa-induced dyskinesia (PD-LID) Epidemiology

The epidemiology segment also provides the Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology data and findings across the United States, Japan, EU4 and the United Kingdom.

The total number of cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID) in the 7MM countries were over 580,000 cases in 2021.

As per the estimates, Germany had the highest prevalent patient population of Parkinson's disease levodopa-induced dyskinesia in 2021. Among EU4 and the UK, Germany had the highest number of cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID), with nearly 67,000 cases, followed by France in 2021. On the other hand, Spain had the lowest number of cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID), with approximately 40,000 cases in 2021.

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Drug Chapters

The drug chapter segment of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) report encloses the detailed analysis of Parkinson's disease levodopa-induced dyskinesia (PD-LID) marketed drugs and late-stage (Phase III, Phase II/III, and Phase II) pipeline drugs. It also helps understand the Parkinson's disease levodopa-induced dyskinesia (PD-LID) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

LID management is often complicated due to its unclear pathogenesis and heterogeneous clinical manifestations. Three types of dyskinesias have been identified: off-period dystonia (least common), peak dose dyskinesia (most common), and diphasic dyskinesia. Furthermore, different types of dyskinesias can respond differently to a particular treatment. So, managing LID remains a matter of grave concern as diagnosing the type of dyskinesia is challenging.

Currently, there is no approved drug therapy for LID that improves activities of daily living, enhances the quality of life, and decreases caregiver burden. Although most patients with PD can tolerate amantadine IR and NOURIANZ drugs, combinations with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. However, once LID has developed, it is irreversible, and termination of L-DOPA treatments worsens the motor symptoms, making LID difficult to control. 

Products detail in the report…

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Emerging Drugs

Drug developers are gradually shifting their attention toward Parkinson's disease Levodopa-induced dyskinesia (PD-LID) to meet the patient pool's current demands and counter the unmet needs of the therapeutic market.

Several companies are working robustly on many new therapies, such as KETARX (PharmaTher), NLX-112 (Neurolixis SAS/Gala laboratories), JM-010 (Bukwang Pharmaceutical/Contera Pharma), AV-101 (Vistagen), Mesdopetam (Ipsen Pharma), XADAGO (Newron Pharmaceuticals/Zambon Pharmaceuticals) and CPL500036 (Celon Pharma SA).

KETARX (PharmaTher) aims to deliver ketamine for intradermal administration to treat various mental health, neurological, and pain disorders. It consists of hydrogel-forming microneedle arrays and an accompanying reservoir that will overcome limitations by the quantity of drug loaded into the needles or onto the needle surfaces. In March 2022, PharmaTher announced positive topline results from the dose-finding and tolerability clinical study (the "Study") of ketamine for treating LID in patients with PD.

NLX-112 (Neurolixis SAS/Gala laboratories) is a novel compound that activates serotonin 5-HT1A receptors. Inhibition of serotonergic neurons is a promising strategy to diminish dyskinesia in PD and can be achieved by targeting serotonin 5-HT1A receptors, which inhibit serotonergic function. NLX-112 is highly effective in reducing abnormal movements in animal models of PD and based on these data, Neurolixis is conducting clinical trials in PD patients who exhibit LID. Presently, NLX-112 is being investigated in Phase II clinical trials for PD-LID.

JM-010 (Bukwang Pharmaceutical/Contera Pharma) is a combination of buspirone, a 5-HT1A agonist, and zolmitriptan, a 5-HT1B/5-HT1D agonist. JM-010 acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to treat disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Phase I clinical safety and Phase II clinical proof of concept studies. JM-010 is being evaluated in Phase II clinical studies in Europe and the US.

Products detail in the report…

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Market Outlook

The Parkinson's disease levodopa-induced dyskinesia (PD-LID) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Parkinson's disease levodopa-induced dyskinesia (PD-LID) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

As per DelveInsight, the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market in the 7MM is expected to change in 2019-2032.

Key Findings

This section includes a glimpse of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market in 7MM. In the 7MM, Parkinson's disease levodopa-induced dyskinesia (PD-LID), the market size was approximately USD 1,500 million in 2021.

The United States: Market Outlook

This section provides the total Parkinson's disease levodopa-induced dyskinesia (PD-LID) market size. It also provides the market size of Parkinson's disease levodopa-induced dyskinesia (PD-LID) by therapies in the United States.

The United States accounts for the highest market size of Parkinson's disease levodopa-induced dyskinesia (PD-LID) than Japan, EU4 and the United Kingdom.

EU4 and the UK: Market Outlook

This section provides the total Parkinson's disease levodopa-induced dyskinesia (PD-LID) market size. It also provides Parkinson's disease levodopa-induced dyskinesia (PD-LID) market size by therapies in Germany, France, Italy, Spain, and the United Kingdom.

Japan Market Outlook

This section provides the total Parkinson's disease levodopa-induced dyskinesia (PD-LID) market size. It also provides the market size of Parkinson's disease levodopa-induced dyskinesia (PD-LID) by therapies in Japan.

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Drugs Uptake

This section focuses on the uptake rate of potential drugs launched or expected to be launched in the market during 2019-2032. The analysis covers Parkinson's disease levodopa-induced dyskinesia (PD-LID) market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and making financial and regulatory decisions.

Parkinson's disease levodopa-induced dyskinesia (PD-LID) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II. It also analyses Parkinson's disease levodopa-induced dyskinesia (PD-LID)'s key players in developing targeted therapeutics.

Major players include PharmaTher, Neurolixis SAS/Gala laboratories, Bukwang Pharmaceutical/Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals/Zambon Pharmaceuticals, and Celon Pharma SA, whose key products are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for emerging Parkinson's disease levodopa-induced dyskinesia (PD-LID) therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the Parkinson's disease levodopa-induced dyskinesia (PD-LID) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging treatment patterns or Parkinson's disease levodopa-induced dyskinesia (PD-LID) market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a competitive and market intelligence analysis of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Parkinson's disease levodopa-induced dyskinesia (PD-LID), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight is provided into the Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Parkinson's disease levodopa-induced dyskinesia (PD-LID) is provided, along with the assessment of new therapies that will impact the current treatment landscape
• A detailed review of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Parkinson's disease levodopa-induced dyskinesia (PD-LID) market

Report Highlights:

• Recently, the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market is set to change due to the rising awareness of the disease and incremental healthcare spending worldwide; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson's disease levodopa-induced dyskinesia (PD-LID) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Parkinson's disease levodopa-induced dyskinesia (PD-LID). The launch of emerging therapies will significantly impact the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market
• For Parkinson's disease levodopa-induced dyskinesia (PD-LID), a better understanding of disease pathogenesis will also contribute to developing novel therapeutics
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the R&D activities

Parkinson's disease levodopa-induced dyskinesia (PD-LID) Report Insights

• Patient Population
• Therapeutic Approaches
• Parkinson's disease levodopa-induced dyskinesia (PD-LID) Pipeline Analysis
• Parkinson's disease levodopa-induced dyskinesia (PD-LID) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Parkinson's disease levodopa-induced dyskinesia (PD-LID) Report Key Strengths

• 11-year Forecast
• 7MM Coverage
• Parkinson's disease levodopa-induced dyskinesia (PD-LID) Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market
• Drugs Uptake

Parkinson's disease levodopa-induced dyskinesia (PD-LID) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights

• What was the market share percentage distribution, and how would it look by 2032?
• What would be the total market size and market size of Parkinson's disease levodopa-induced dyskinesia (PD-LID) by therapies across the 7MM forecast period (2019-2032)?
• What are the key findings about the market across 7MM, and which country will have the largest Parkinson's disease levodopa-induced dyskinesia (PD-LID) market size during the forecast period (2019-2032)?
• At what CAGR is the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market expected to grow in the 7MM forecast period (2019-2032)?
• What would be the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market outlook across the 7MM forecast period (2019-2032)?
• What would be the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market growth until 2032 and the resultant market size by 2032?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• What is the historical patient pool of Parkinson's disease levodopa-induced dyskinesia (PD-LID) covering the United States, Japan, EU4 and the UK?
• What would be the forecasted patient pool of Parkinson's disease levodopa-induced dyskinesia (PD-LID) covering the United States, Japan, EU4 and the UK?
• What will be the growth opportunities in the 7MM concerning the patient population of Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• Out of all the 7MM, which country would have the highest prevalence of Parkinson's disease levodopa-induced dyskinesia (PD-LID) during the forecast period (2019-2032)?
• At what CAGR is the population expected to grow in the 7MM forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• What are the current treatment guidelines for treating Parkinson's disease levodopa-induced dyskinesia (PD-LID) in the US, Europe, and Japan?
• What are the Parkinson's disease levodopa-induced dyskinesia (PD-LID) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• How many therapies are developed by each company to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• How many emerging therapies are in the mid-stage and late stages of development to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Parkinson's disease levodopa-induced dyskinesia (PD-LID) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and its status?
• Which key designations have been granted for the emerging therapies for Parkinson's disease levodopa-induced dyskinesia (PD-LID)?
• What are the global historical and forecasted Parkinson's disease levodopa-induced dyskinesia (PD-LID) markets?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market
• To understand the future market competition in the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market and an insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Parkinson's disease levodopa-induced dyskinesia (PD-LID) in the US, Japan, Europe (Germany, Spain, Italy, France), and the United Kingdom
• Identifying upcoming solid players in the market will help devise strategies that will help get ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market
• To understand the future market competition in the Parkinson's disease levodopa-induced dyskinesia (PD-LID) market